Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: J Allergy Clin Immunol. 2011 Jan;127(1):161–166.e1. doi: 10.1016/j.jaci.2010.10.035

Table 3.

Incremental Cost Effectiveness Ratio for fluticasone vs. montelukast during the study period 1

ΔDC
ΔACD		 ΔDC
ΔFEV		 ΔDC
Avoided Exacer 1 		ΔSC
ΔACD		 ΔSC
ΔFEV		 ΔSC
Avoided Exacer 1
−11 (−6, −42) −13 (−26, −9) −916 (−2095, −531) −15 (−55, −8) −19 (−10, −38) −1272 (−2616, −745)
1

ICER=Δcost/Δeffect, where Δ stands for difference between fluticasone and montelukast. DC: direct costs; SC: societal costs. The negative sign of ICER resulted from the fact that fluticasone had lower costs and higher effectiveness than montelukast. The negative sign of 95% CI indicated that the dominance of fluticasone held at least 95% of the time.